Overview of Results

Through our integrated drug discovery process, Vitae Pharmaceuticals has generated the following disclosed programs, targeting promising therapeutic areas of substantial unmet medical need and commercial value.

  • Chronic kidney disease - VTP-27999, Vitae Pharmaceuticals' wholly owned renin inhibitor which has completed Phase I studies, is designed to improve the treatment of patients with chronic kidney disease.
    • Renin is the first and rate-limiting step in the renin-angiotensin-system (RAS) pathway. RAS components are located in critical organs throughout the body (kidney, heart, brain) and RAS activity has direct effects on tissues, playing a key role in kidney damage.
  • Diabetes - Vitae Pharmaceuticals' diabetes program, partnered with Boehringer Ingelheim, focuses on inhibition of 11ß-hydroxysteroid dehydrogenase (HSD)-1 for the treatment of diabetes and associated metabolic diseases.
    • 11ß-HSD-1 is a recently validated, new diabetes target which has shown broad potential metabolic syndrome benefit.
  • Alzheimer's disease - Vitae Pharmaceuticals' beta-secretase (BACE) program, also partnered with Boehringer Ingelheim, has identified potent and bioavailable inhibitors that have demonstrated the ability to cross the blood-brain barrier and significantly lower brain amyloid-beta (Aß or Abeta) peptide following a single oral dose in preclinical, in vivo models of Alzheimer's disease.
    • Inhibition of BACE, an enzyme involved in the formation of amyloid-beta plaques that accumulate in the brains of patients with Alzheimer's disease, is a leading prospect for slowing or even halting disease progression.

 

  • Atherosclerosis - Vitae Pharmaceuticals has initiated a program to treat atherosclerosis by modulating LXR, an approach that increases reverse cholesterol transport (RCT), decreases inflammation and is complimentary to the LDL-lowering capabilities of statins.
    • In 12 months, Vitae scientists have discovered novel, small molecule compounds that induce the expression of RCT biomarkers without the induction of triglycerides in rodent and primate models.

All of Vitae Pharmaceuticals' programs integrate its proprietary, structure-based drug design platform, CONTOUR®, with the experience and insights of a world-class scientific team.

 

The focused combination of novel platform, unique process and talented people has created a highly efficient, fast and value producing discovery engine.